In recent trading session, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) saw 2.61 million shares changing hands at last check today with its beta currently measuring 0.92. Company’s recent per share price level of $6.07 trading at -$0.1 or -1.62% at last check today assigns it a market valuation of $2.44B. That most recent trading price of RXRX’s stock is at a discount of -103.62% from its 52-week high price of $12.36 and is indicating a premium of 7.74% from its 52-week low price of $5.60. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 23.99 million shares which gives us an average trading volume of 23.52 million if we extend that period to 3-months.

For Recursion Pharmaceuticals Inc (RXRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.52 in the current quarter.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information

Upright in the red during last session for losing -1.62%, in the last five days RXRX remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $6.07 price level, adding 8.58% to its value on the day. Recursion Pharmaceuticals Inc’s shares saw a change of -10.21% in year-to-date performance and have moved -2.72% in past 5-day. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) showed a performance of -20.76% in past 30-days. Number of shares sold short was 80.72 million shares which calculate 2.51 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a fall of -1.17% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would jump 1.15% in reaching the projected high whereas dropping to the targeted low would mean a gain of 1.15% for stock’s current value.

Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts

This year revenue growth is estimated to rise 62.88% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 18.12M for the same. And 6 analysts are in estimates of company making revenue of 19.78M in the next quarter. Company posted 13.79M and 14.42M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -35.28% during past 5 years.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders

Insiders are in possession of 3.60% of company’s total shares while institution are holding 77.00 percent of that, with stock having share float percentage of 79.87%. Investors also watch the number of corporate investors in a company very closely, which is 77.00% institutions for Recursion Pharmaceuticals Inc that are currently holding shares of the company. ARK INVESTMENT MANAGEMENT LLC is the top institutional holder at RXRX for having 28.14 million shares of worth $211.07 million. And as of 2024-06-30, it was holding 11.6199 of the company’s outstanding shares.

The second largest institutional holder is BAILLIE GIFFORD & CO, which was holding about 26.59 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.9787 of outstanding shares, having a total worth of $199.42 million.

On the other hand, ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 18.28 shares of worth $111.13 million or 4.63% of the total outstanding shares. The later fund manager was in possession of 11.59 shares on Dec 31, 2024 , making its stake of worth around $70.45 million in the company or a holder of 2.93% of company’s stock.